Krystal Completes Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB

Krystal Completes Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB

311319

Krystal Completes Phase 3 Trial of B-VEC, Topical Gene Therapy for DEB

Topline data should be available toward the end of this year for a Phase 3 clinical trial testing B-VEC (beremagene geperpavec), a topical gene therapy for treating skin wounds in patients with dystrophic epidermolysis bullosa (DEB). Krystal Biotech, the therapy’s developer, announced that the last of the 31 participants in the study had completed the 26-week (six-month) dosing period and 30-day safety follow-up visit. “We want to express our gratitude to the trial participants, their families, the clinical…

You must be logged in to read/download the full post.